Breaking News

Owl, Abliva Partner on Traumatic Brain Injury Drug

Agreement provides Owl Therapeutics with a global license to develop, manufacture, and commercialize NeuroSTAT.

Owl Therapeutics, a wholly owned subsidiary of Gryphon Bio, entered into a global licensing and collaboration agreement with Swedish-based Abliva AB to advance Abliva’s NeuroSTAT (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI). Under the terms of the agreement, Abliva will contribute to both the operational and strategic elements of the program through the established steering committee. Owl Therapeutics will lead the clinical development a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters